CJC-1295 No-DAC
PeptideThe substantial divergence of -44 points arises from the absence of published RCTs specific to CJC-1295 No-DAC [s1] and significant safety concerns raised by the FDA [s4, s10], while community reports describe subjective improvements in body composition and recovery that have not been methodologically validated [c1, c2, c3].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Not a single published controlled human trial exists specifically for CJC-1295 without DAC — all evidence derives from the DAC variant and preclinical models. The short half-life of ~30 minutes produces a more physiological, pulsatile GH pattern but demands multiple daily injections, making it impractical. Community reports are mostly positive, but almost exclusively for the combination with Ipamorelin — as monotherapy, the compound is widely considered ineffective. No regulatory approval; human use is not legally permissible in Germany.
Description
Short-acting synthetic GHRH analogue (half-life ~30 min) that stimulates pulsatile growth hormone secretion; not FDA-approved [s1, s4].
CJC-1295 without DAC (also known as Mod GRF 1-29) is a synthetic 29-amino acid analogue of endogenous growth hormone-releasing hormone (GHRH). Compared to native GHRH, four amino acids have been substituted to slow enzymatic degradation and extend the half-life from a few minutes to approximately 30 minutes [s2, s3]. The key difference from the "with DAC" (Drug Affinity Complex) version is that CJC-1295 No-DAC does not contain an albumin-binding maleimide molecule. This results in a substantially shorter plasma half-life (approximately 30 minutes vs. 6–8 days) and produces a pulsatile pattern of GH release that more closely resembles physiological secretion [s2, s3]. Clinical evidence for CJC-1295 No-DAC is limited. Most published data refers to CJC-1295 with DAC (Walker et al., 2006), not the No-DAC variant. Preclinical and limited clinical data suggest dose-dependent increases in GH and IGF-1 [s1]. In the biohacking community, it is frequently combined with Ipamorelin to generate synergistic GH pulses [s5, s6]. CJC-1295 No-DAC is not approved by the FDA, EMA, or BfArM for any clinical indication. It is classified by WADA under category S2 as a prohibited substance [s7, s8]. The FDA has explicitly classified CJC-1295 as a substance with potentially significant safety risks when used in compounding pharmacy preparations [s4, s10].
Legal Status (DE)
Not approved as a medicinal product in Germany. No EMA or BfArM authorization. Distribution for human consumption violates §21 AMG. Predominantly marketed as a research chemical. Purchase and possession for research purposes exist in a legal grey area. In sport, CJC-1295 is prohibited year-round by WADA under category S2 [s7, s8, s9].
Mechanism of Action
CJC-1295 No-DAC selectively binds to the GHRH receptor (GHRHR) on somatotroph cells of the pituitary gland. This binding activates the Gs protein/cAMP signaling pathway, leading to the synthesis and secretion of endogenous growth hormone (GH) [s1, s5]. Since the No-DAC variant does not carry an albumin-binding DAC molecule, the peptide is rapidly degraded by dipeptidyl peptidase IV (DPP-IV) and other serum proteases. This results in a plasma half-life of approximately 30 minutes and produces a pulsatile GH release pattern that more closely approximates physiological secretion than the continuous elevation produced by CJC-1295 with DAC [s2, s3]. The rise in GH secondarily leads to hepatic production of insulin-like growth factor 1 (IGF-1), which mediates anabolic and lipolytic effects. The biological effector cascade includes: increased protein synthesis in muscle cells, lipolysis in adipose tissue, and improvement of sleep architecture (increased slow-wave sleep fraction via GHRH activity in the brainstem) [s5, s6]. In combination with Ipamorelin (a GH secretagogue at GHS-R1a receptors), a synergistic effect occurs: CJC-1295 No-DAC amplifies the GHRH signal, while Ipamorelin triggers the actual GH release [s5, s6].
Dosing
GH-Pulsoptimierung (Monotherapie)
- Dose
- 100–300 mcg per injection
- Frequency
- 1–3× täglich
- Route
- injektion-subkutan
- Duration
- Zyklen von 8–12 Wochen üblich in Community; klinisch nicht validiert
- Timing
- Fasted, at least 30 minutes before meals or immediately before bedtime
- With food
- vermeiden
Kombinationsprotokoll mit Ipamorelin
- Dose
- 100–200 mcg CJC-1295 No-DAC + 200–300 mcg Ipamorelin
- Frequency
- 1–2× täglich
- Route
- injektion-subkutan
- Duration
- Klinisch nicht validiert; Community-Protokoll variabel
- Timing
- Fasted, 30 minutes before a meal; often in the evening before sleep
- With food
- vermeiden
No clinically validated upper limit for CJC-1295 No-DAC. Community protocols rarely exceed 300 mcg per injection. Any dosage above this threshold is not supported by human studies [s11, s12].
Reconstitution: a 10 mg vial with 3 mL bacteriostatic water yields approximately 3,333 mcg/mL. Administer subcutaneously using a U-100 insulin syringe [s11, s12]. All protocols are unsupported by approved clinical studies for the No-DAC variant. Human use outside of clinical trials is not legally permissible in Germany [s7, s9].
Calculate reconstitution, plan dosing, look up injection technique
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Injektionsstellenreaktionen (Erythem, leichte Schwellung, Schmerz) Documented as the most common adverse effect in limited clinical reports and community data [s1, s13]. | häufig | leicht |
| Vorübergehende Gesichtsrötung (Flush) Vasodilatory effect due to GH elevation; described in community reports and clinical observations [s13]. | gelegentlich | leicht |
| Wasserretention / leichte Ödeme GH-induced antinatriuretic effects; known adverse effect of GH secretagogues [s6, s13]. | gelegentlich | leicht |
| Vorübergehende Erhöhung des Blutzuckers GH-induced insulin resistance; documented for GHRH analogues and GH secretagogues in general [s14, s15]. | gelegentlich | moderat |
| Kopfschmerzen, Schwindel Occasionally mentioned in community reports; mechanistically plausible via GH fluctuation [c2, c5]. | gelegentlich | leicht |
| Kribbeln/Taubheitsgefühl (Karpaltunnel-ähnlich) Known adverse effect at elevated GH levels; also described for related GHRH analogues [s6, s15]. | selten | leicht |
| Unerwünschte Tumorpromotion (theoretisch) GH and IGF-1 can promote cell proliferation; theoretically risk-bearing in pre-existing malignancies. No direct evidence for CJC-1295 No-DAC [s6, s10]. | theoretisch | schwer |
| Schwerwiegende unerwünschte Ereignisse (kontaminierte Produkte) FDA document references deaths in studies with related GH secretagogues; contamination risk from uncontrolled sources is substantial [s10]. | selten | schwer |
Contraindications
GH/IGF-1 axis activation may promote tumor growth; generally contraindicated for GH therapy [s6, s15].
GH elevation causes insulin resistance and may worsen glycemic control [s14, s15].
Additional GH stimulation is contraindicated in the presence of already elevated GH levels [s6].
No safety data available for pregnant or breastfeeding women; use is not justifiable [s6, s10].
Uncontrolled GH stimulation in still-growing bones is potentially dangerous [s6].
GH secretagogues may reduce efficacy and affect hormone levels in hypothyroidism [s6].
CJC-1295 is on the WADA prohibited list category S2; use results in disqualification [s7, s8].
Interactions
Synergistic
Synergistic effect on GH secretion: CJC-1295 No-DAC amplifies the GHRH signal, while Ipamorelin triggers GH release via a complementary receptor [s5, s6].
Oral GH secretagogue; mechanistically complementary to GHRH analogues, combined effect on the GH axis theoretically possible [s6].
The combination of CJC-1295 No-DAC with BPC-157 is used for enhanced tissue healing and recovery. BPC-157 supports repair of tendons, ligaments, and muscles, while CJC-1295 promotes GH-mediated regeneration.
TB-500 combined with CJC-1295 No-DAC is described as the so-called "Wolverine Stack" in regeneration research. The combination is purported to synergistically support muscle and joint rehabilitation.
GHRP-2, like Ipamorelin, belongs to the class of growth hormone-releasing peptides and acts synergistically with CJC-1295 No-DAC via complementary receptor pathways. The combination markedly increases GH pulsatility.
GHRP-6 acts synergistically with CJC-1295 No-DAC, increasing both GH and IGF-1 levels without significant elevation of prolactin. This combination is well documented in preclinical studies.
Hexarelin, as a potent GHRP, can be used together with CJC-1295 No-DAC to maximize GH secretion via two distinct receptor pathways.
Caution
GH-induced insulin resistance may necessitate dose adjustments; blood glucose monitoring required [s14, s15].
Glucocorticoids inhibit GH secretion and may attenuate the effect of CJC-1295 No-DAC [s6].
GH secretagogues may affect thyroid metabolism; monitoring recommended [s6].
Studies
Tier A — High Evidence
Outcome: Pharmacokinetics, pharmacodynamics (GH and IGF-1 increases), and safety of CJC-1295 WITH DAC in healthy adults
Effect Size: Dose-dependent, sustained GH increases; no serious adverse events. Note: study investigates CJC-1295 with DAC, not the No-DAC variant.
Tier B — Moderate Evidence
Outcome: Body composition, metabolism, and safety of GH therapies in older adults
Effect Size: GH treatment improves body composition but increases adverse event rate; GH therapy not recommended as anti-aging [s15].
Outcome: Safety and efficacy of GH in healthy older adults
Effect Size: Limited RCT data show small effects on body composition with increased adverse event rate; GH not recommended as anti-aging therapy.
Tier C — Low Evidence
Outcome: Half-life comparison of CJC-1295 with vs. without DAC
Effect Size: No-DAC: half-life ~30 minutes; with DAC: ~6–8 days.
Outcome: Structural and pharmacokinetic differences between CJC-1295 variants
Effect Size: No-DAC produces a pulsatile GH pattern; DAC form produces a continuous GH increase.
Community Evidence
Top reported benefits
- Improved deep sleep and recovery quality
- Moderate fat loss (particularly in the abdominal area)
- Improved muscle recovery after training
- Mild increase in muscle strength and definition
- Elevated IGF-1 levels (laboratory-confirmed in individual users)
Top reported issues
- Injection site reactions (redness, swelling)
- No dramatic results when used alone without Ipamorelin
- Short half-life requires frequent injections (practically inconvenient)
- Uncertainty about product purity and quality from uncontrolled sources
- Headaches and transient fatigue
Several users highlight uncertainty regarding product quality from unregulated sources [c4, c5]. Isolated reports of absent effects, possibly attributable to contaminated or underdosed products. Community consensus is that CJC-1295 No-DAC alone is less effective than in combination with Ipamorelin [c1, c2, c3]. Long-term safety data from controlled studies are entirely lacking.
Scientific Sources
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Walker RF, Codd EE, Baez M, et al. (2006). Journal of Clinical Endocrinology & MetabolismAPMID:16352683DOI - An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs
Engelberg J, et al. (2024). ProPublicaBLink - CJC-1295 No DAC Dosage Protocol — Educational Guide
PeptideDosages Editorial Team (2024). PeptideDosages.comCLink - CJC-1295 No DAC Peptide Dosing Guide: Mod GRF, Timing & Safety (2026)
PeptideDosing Protocols Editorial Team (2026). PeptideDosing Protocols.comCLink - Is CJC-1295 Safe? Side Effects Explained
Real Peptides Editorial Team (2024). RealPeptides.coCLink - Mod GRF 1-29/Ipamorelin Dosage — Side Effects and Clinical Notes
The Peptide Report Editorial Team (2024). ThePeptideReport.comCLink - Systematic review: the safety and efficacy of growth hormone in the healthy elderly
Liu H, Bravata DM, Olkin I, et al. (2007). Annals of Internal MedicineAPMID:17227934DOI - CJC-1295 DAC vs CJC-1295 Without DAC: Research Differences, Half-Life & Laboratory Applications
Loti Labs Research Team (2024). Loti Labs ResourcesCLink - CJC-1295 With DAC vs Without DAC: A Research Guide to Half-Life, GH Pulse Patterns & Laboratory Dosing Models
SourcePeptides Research Team (2026). SourcePeptides.coCLink - FDA Briefing Document Pharmacy Compounding Advisory Committee (PCAC) Meeting — Peptides Including CJC-1295
U.S. Food and Drug Administration (2024). U.S. Food and Drug AdministrationALink - CJC-1295 and Ipamorelin: Growth Hormone Stack Guide
Medsbase Editorial Team (2024). Medsbase.comCLink - Growth hormone and aging: a clinical review
Bartke A, Sun LY, Dhahbi J, et al. (2025). Frontiers in AgingBDOI - The Prohibited List 2024 — World Anti-Doping Agency
World Anti-Doping Agency (2024). WADAALink - CJC-1295 Use in Sports and Military Rules Explained
BSCG Editorial Team (2024). BSCG.orgBLink - CJC-1295 Deutschland — Forschungsguide: Rechtliche Einordnung
Peptide Library Editorial Team (2024). Peptidelibrary.ioBLink
Community Sources
Storage
Unopened
Lyophilized powder: stable for up to 24 months when stored at -20°C; protect from light.
Opened
Reconstituted solution: store at 2–8°C (refrigerator) for a maximum of 28–30 days; do not freeze after reconstitution.
Notes
Use bacteriostatic water for reconstitution (extends shelf life compared to sterile water). Protect vials from light and heat. Do not use any solution that contains particles or appears discolored [s11, s12].